European Urology Today Official newsletter of the European Association of Urology
14
Vol. 33 No.2 - March/May 2021
Genital gender affirmation surgery
The e-informed patient
Digital uropathology in times of COVID-19
ESGURS update on penile reconstruction
Pros and cons of patient’s internet search
ESUP update on remote diagnosis, consultation and distant teaching
Mr. Wai Gin (Don) Lee
23
27
Dr. Markos Karavitakis
Prof. Rodolfo Montironi
Get ready for the EAU21 Virtual Congress! A preview of the hottest topics that will be discussed this summer As a preview of the EAU21 Scientific Programme, we spoke to seven experts who were involved in abstract selection and developing the plenary and thematic sessions. Get a glimpse of the EAU’s 36th Annual EAU Congress, the event of the year! Registration will remain open until 12 July, but the discounted early fee is only available until 1 June. See www.eau2021.org for all the available registration fees, the scientific programme and, of course, the latest congress-related news.
e Science at Europe’s largest Urology Congress
Join us!
Prof. Jean-Nicolas Cornu (Rouen, FR): Incontinence
2021.org
“Urinary incontinence is one of the most frequent urological conditions, especially in the elderly population. The impact of population ageing is already seen in urology wards where patients are older and older. During #EAU21 Virtual congress, a specific focus will be made on UI in the elderly, discussing overactive bladder treatments and surgical options. These options include bulking agents, slings, and artificial urinary sphincter. We will also specifically look at drugs: how and when to use them in daily practice.”
Prof. Evangelos Liatsikos (Patras, GR): Stones and endourology
Prof. Marc-Oliver Grimm (Jena, DE): Renal cell cancer
“Stones is always an
“Renal cell cancer (RCC) is
interesting and relevantScience part evolving rapidlylargest with regard to Urology Congress Cutting-edge at Europe’s
of urology, it represents a big part of the activities that urologists are doing in their practice. A lot of urologists combine the treatment of urological stones with another specialty. Around 40-50% of our practice is stones so it’s always an interesting topic to discuss.” “At EAU21 we will cover what is new in stone management. The track is designed to cover every part, from shockwave lithotripsy to percutaneous nephrolithotripsy (PCNL) and flexible ureteroscopy. We will discuss hot topics like metabolic evaluation, the medical treatment of urinary stones, and suggested dietary modifications. Stone analysis and the basic evaluation of stone patients are of use to us. We will also see a case discussion on a young boy, in order to address the paediatric side of stone treatment.” “Of course endourology is closely linked to developments in technology. So delegates can also expect us to cover everything to do with single-use ureteroscopes, and new developments in laser technology. These technologies evolve almost on a year-by-year basis. It’s important that people hear from the experts what is not just new but also what is objectively an improvement and useful in daily practice.”
“Finally, we will also look at surgical training and how this can be done in times of pandemic. Perhaps virtual training will play a larger role for our younger colleagues?”
Associated Plenary Session Plenary Session 7: Stones: Keeping with tradition or time for new concepts? Monday, 12 July (8:00-9:30)
molecular, diagnostic and treatment research and its implementation in clinical practice. The VHL mechanism in RCC is a good example and all its aspects will be discussed to set the scene of this session. This is a special lecture on behalf of the Society of Urologic Oncology (SUO). For the small renal mass, an update will be given on different approaches and will help you to make the right decision.”
Prof. Morgan Roupret (Paris, FR): Advanced bladder cancer “Scientific efforts of the last decade have yielded several novel diagnostic and therapeutic opportunities for patients suffering from localized muscle-invasive bladder cancer (MIBC) and metastatic disease. The management of patients with high-risk MIBC remains an unmet need. The EAU scientific committee office came up with a very challenging session for EAU21.” “To date, several definitions have been applied to determine which patients are considered at high-risk of recurrence after curative intent following radical cystectomy (RC). The current therapies that have arisen on the bladder cancer BC armamentarium have generated a myriad of options in terms of medical and surgical therapies, as well as optimal sequencing strategies. At EAU21 we will be looking at the increasing popularity of PET/CT for the staging of advanced bladder cancer, and what is the most appropriate preinterventional staging modality.”
“Experts in incontinence will also discuss pragmatic clinical situations in both sexes, e.g. an artificial sphincter dysfunction in an elderly male, and a case of stress urinary incontinence in an elderly female candidate for surgery. Key opinion leaders will also cover the growing legal and regulatory issues in the field of mesh implantation, and focus on the patient’s perspective.” “Beyond the plenary session, the rest of the EAU21 programme will also cover hot topics related to incontinence. This includes poster and thematic sessions on cutting-edge scientific reports, updated clinical trials results, and presentations on new instruments and devices.”
Associated Plenary Session Plenary Session 2: Optimal management of incontinence in the elderly patient Friday, 9 July (10:30-12:00)
“In larger tumours there has recently been a shift in surgery towards more nephron sparing. A pro and con discussion on this issue will help delegates finetune their clinical practice. In the mRCC setting prospective randomised trials tried to answer the role of nephrectomy in different eras of systemic therapy. The choice can be individualised and is also dependent on new treatment possibilities. Look forward to a mix of pre-recorded lectures by experts and interactive live discussion led by the session chairmen.”
Prof. Silke Gillessen (Bellinzona, CH): Advanced PCa “I think every urologist that deals with metastatic PCa will find something of interest at EAU21, particularly the plenary session. It’s a dynamic field and we’ve seen a lot of new developments in the last five years.”
metastatic disease after they have primary treatment. It seems that biologically these groups are different and have a different prognosis. Delegates can look forward to learning about which patients could benefit from which treatments.”
www.eau2021.org
“For instance, there are a lot of new treatment options for metastatic, hormone-sensitive PCa. We don’t yet know which option is best for which patient. We’re learning more and more that this is not one group of patients, but that there are differences between patients with, for example, high or low-volume disease, or patients who are de novo metastatic or patients who relapse with
“In the coming months we’re also expecting new data on the combination of different treatment options. We might have started about 40 years ago with hormonal treatment and androgen deprivation therapy alone. But adding chemotherapy or novel hormonal agents can be beneficial. For instance, the addition of radiotherapy for patients with low-volume disease can give an overall survival benefit. We will also soon know the effects of triple combinations, for instance ADT plus a novel hormonal agent, and also docetaxel. Or combining ADT, radiotherapy, abiraterone and docetaxel. Triple
Associated Plenary Session Plenary Session 4: Renal cancer: From localised to metastatic disease Saturday, 10 July (11:00-12:30)
Join us!
“The EAU Guidelines provide clear statements regarding the usage of perioperative systemic therapy in patients with MIBC. Then should we always perform a radical cystectomy after completer response? Our advanced bladder cancer plenary session will host a debate on the topic.” “Immunotherapy has recently brought a paradigm shift on treatment options for several cancers. In bladder cancer, several treatment options are currently available on metastatic disease. These outcomes provided the rationale to attempt utilization on an early phase of the disease. We will be exploring neo-adjuvant immunotherapy.” “And last but not least, molecular markers appears to be a the ‘new kids on the block.’ Many efforts have been recently made to classify urothelial carcinoma of the bladder from a molecular point of view, which has several implications for treatment choices and prognosis. This is a hot topic at EAU21 and we will see if molecular markers are suitable for being used currently in daily practice.”
Associated Plenary Session Plenary Session 3: Advanced bladder cancer in 2021: Going forward? Saturday, 10 July (11:00-12:30)
or quadruple combinations give us a lot of potential therapeutic options.” “Additional topics that we will discuss in the plenary, thematic and abstract sessions include the potential of personalised medicine, and differentiating between patients who will benefit versus those who won’t. Case presentations are a useful way to illustrate this. We will also look at new, more sensitive imaging options and imaging-guided treatment. Delegates can likely also expect analyses from ongoing trials in the ‘late breaking’ session.”
Associated Plenary Session: Plenary Session 5: Treatment for metastatic hormone-sensitive prostate cancer Sunday, 11 July (11:45-13:15) Continued on page 2
March/May 2021
European Urology Today
1
